BSD Medical Ships BSD-2000/3D/MR Image Guided Hyperthermia System for Installation at Erasmus Medical Center Cancer Institute...
April 22 2014 - 11:00AM
Business Wire
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD)
(www.BSDMedical.com), a leading provider of medical systems that
utilize heat therapy to treat cancer, announced today that the
Company has shipped a BSD-2000/3D/MR Image Guided Hyperthermia
System (BSD-2000/3D/MR) to Dr. Sennewald Medizintechnik GmbH. The
BSD-2000/3D/MR will be installed at the Erasmus MC Cancer Institute
(Erasmus) - Daniel den Hoed Cancer Center. The BSD-2000/3D/MR
system integrates a BSD-2000/3D Hyperthermia System with Magnetic
Resonance (MR) imaging to deliver targeted image guided
hyperthermia therapy, while simultaneously providing non-invasive
imaging of the diseased tissue as well as the surrounding healthy
tissue. The magnetic resonance images are color graded to show
temperature changes in the treatment area during hyperthermia
therapy.
The Erasmus system will be the sixth BSD-2000 System with
integrated MR capability purchased by prestigious educational
institutions in Europe. Similar systems have also been installed at
the Munich Grosshadern UMS, Berlin Charité UMS, Erlangen UMS,
Tuebingen UMS, and Duesseldorf UMS, all in Germany.
About Erasmus MC Cancer Institute
Erasmus MC Cancer Institute is in the top 10 most prestigious
medical centers in Europe and the largest academic teaching
hospital in The Netherlands. Erasmus MC Cancer Institute - Daniel
den Hoed Cancer Center, is internationally recognized for its
dedicated patient care and innovative and groundbreaking medical
research in oncology. The Hyperthermia Unit of the Department of
Radiation Oncology at Erasmus MC is one of the leading hyperthermia
treatment centers in the world, and the department operates 14
linear accelerators with state-of-the-art technology. This is the
second BSD-2000 Hyperthermia System purchased by Erasmus MC. The
Erasmus MC hyperthermia unit already operates a BSD 2000/3D system
for routine pelvic hyperthermia patient treatments as well as an
array of other hyperthermia systems for the treatment of local
disease. Erasmus MC has been instrumental in the development of
hyperthermia from a promising field of research to an accepted
therapy for the treatment of cancer. Erasmus MC was also
instrumental in assisting BSD in obtaining FDA Humanitarian Device
Exemption approval of the BSD 2000 through its Phase III,
multicenter, clinical study on hyperthermia combined with
radiotherapy compared with radiotherapy alone, which was published
in The Lancet. one of the most prestigious scientific medical
journals in the world with an impact factor of 39·06.
About the BSD-2000 Hyperthermia System
The BSD-2000 – developed and patented exclusively by BSD –
delivers localized therapeutic heating (hyperthermia) by applying
radiofrequency (RF) energy. The BSD-2000 creates a central focusing
of energy that can be electronically focused to target the shape,
size and location of the tumor, thus providing dynamic control of
the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the
U.S. Food and Drug Administration (FDA) for use in conjunction with
radiation therapy for the treatment of cervical cancer patients who
are ineligible for chemotherapy. The BSD-2000 also has CE
(Conformité Européenne) Marking approval for the commercial sale in
Europe. CE Marking approval is also recognized in many countries
outside of the EU. The BSD-2000/3D/MR has received CE Marking
approval.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and
services systems to treat cancer and benign diseases using heat
therapy, which is delivered using focused radiofrequency (RF) and
microwave energy. BSD’s product lines include both hyperthermia and
ablation treatment systems. BSD’s hyperthermia cancer treatment
systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other
therapies such as radiation therapy. BSD’s microwave ablation
system has been developed as a stand-alone therapy to employ
precision-guided microwave energy to ablate (destroy) soft tissue.
The Company has developed extensive intellectual property, multiple
products in the market and established distribution in the United
States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States,
Europe and China. For further information visit BSD Medical's
website at www.BSDMedical.com.
This press release may be deemed to contain forward-looking
statements, which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Readers are
cautioned that these forward-looking statements are only
predictions and may differ materially from actual future events or
results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company
to produce the products to meet the demand, global economic
conditions and uncertainties in the geopolitical environment and
other risk factors set forth in the Company’s most recent reports
on Form 10-K and Form 10-Q. Any forward-looking statements in this
release are based on limited information currently available to the
Company, which is subject to change, and the Company will not
necessarily update the information.
BSD Medical CorporationWilliam Barth, (801) 972-5555Facsimile:
(801) 972-5930investor@bsdmc.com